Condition: Ventricular Arrhythmia · Cardiomyopathies · Left Ventricular Ejection Fraction Less Then or Equal to 50percent · Sponsor: University Hospital, Bordeaux
EP-SCOPE is a prospective, multicentric, non-randomized pilot study that aims to estimate the risk of life-threatening ventricular arrhythmia through use of advanced electrophysiological studies in patients with ischemic or non-ischemic cardiomyopathy with left ventricular ejection fraction (LVEF) \<50% and risk factors of ventricular arrhythmia, otherwise not considered for implantation of an implantable cardioverter defibrillator (ICD). The objective is to assess the effectiveness of a risk stratification strategy based on detailed electrophysiological exploration of the left ventricle and programmed ventricular stimulation.
This description comes directly from the study's public registry record.
Sylvain PLOUX, MD · +33(0)5 57 65 64 71 · sylvain.ploux@chu-bordeaux.fr
Mélissa LABEQUE · +33(0)5 57 62 31 32 · melissa.lavevre@chu-bordeaux.fr
Always discuss trial participation with your own doctor first.
| CHU de Clermont-Ferrand | Clermont-Ferrand, France | Recruiting |
| CHU de Bordeaux - Hôpital Cardiologique du Haut-Lévêque | Pessac, France | Recruiting |
| CHU de Saint-Etienne | Saint-Etienne, France | Recruiting |
Get one email when the public record changes — results posted, or the study's status changes. Nothing else, ever.
We email about this public record only. Unsubscribe anytime with one click. Never medical advice.
This page is independently generated by Eichor from the public ClinicalTrials.gov record and re-synced daily. It is not the sponsor's official website unless claimed. Nothing here is medical advice; eligibility is always determined by the study team — talk to your own doctor first.
Source record: clinicaltrials.gov/study/NCT07020702